Nanoscintillators as Next-Generation Radiotherapeutics: Bridging Physics, Chemistry, and Oncology
Bioconjugate Chemistry · 2025
DOI: 10.1021/acs.bioconjchem.5c00249 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioconjugate Chemistry, 2025. Verfasst von Kristel Bedregal-Portugal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Grenoble Alpes University, Inserm U1209, CNRS UMR 5309, Cancer Targets and Experimental Therapeutics, Institute for Advanced Biosciences, 38000 Greno…. Hauptthemen laut MEDLINE: Neoplasms, Nanoparticles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 131 Literaturangaben. Gefördert von: National Cancer Institute, European Research Council.
Abstract (Originalsprache)
Scintillating nanoparticles, or nanoscintillators, are a promising class of radiotherapeutic agents that present novel opportunities to enhance the efficacy and precision of conventional radiation therapy in cancer treatment. These nanoparticles possess the unique ability to convert ionizing radiation, such as X-rays, into visible light emission, which can, in turn, activate a variety of secondary therapeutic modalities, such as photodynamic therapy, within the tumor microenvironment. By enabling therapeutic mechanisms that are mechanistically distinct from those of ionizing radiation, nanoscintillators offer a multifaceted strategy to overcome tumor resistance and improve treatment outcomes. This Review aims to provide a focused exploration of the fundamental principles, design strategies, and emerging translational applications of scintillating nanoparticles in nanomedicine. Rather than present an exhaustive survey, we highlight key developments, current challenges, and future directions that define the state of this rapidly evolving field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Grenoble Alpes University, Inserm U1209, CNRS UMR 5309, Cancer Targets and Experimental Therapeutics, Institute for Advanced Biosciences, 38000 Grenoble, France.
- Grenoble Alpes University, CHU Grenoble Alpes, Service de Radiothérapie, 38000 Grenoble, France.
- Grenoble Alpes University, Inserm UA7, Synchrotron Radiation for Biomedicine, 38000 Grenoble, France.
- Grenoble Alpes University, Inserm UA7, CHU Grenoble Alpes, Service de Radiothérapie, 38000 Grenoble, France.
ORCID-Profile: Anne-Laure Bulin
Förderung
- National Cancer Institute
- European Research Council
Zitieren
APA
Bedregal-Portugal, K., Mercier, A., Stelse-Masson, S., Aubrun, C., Elleaume, H., Verry, C., & Bulin, A. L. (2025). Nanoscintillators as Next-Generation Radiotherapeutics: Bridging Physics, Chemistry, and Oncology. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00249
Vancouver
Bedregal-Portugal K, Mercier A, Stelse-Masson S, Aubrun C, Elleaume H, Verry C, et al. Nanoscintillators as Next-Generation Radiotherapeutics: Bridging Physics, Chemistry, and Oncology. Bioconjugate Chemistry. 2025. doi:10.1021/acs.bioconjchem.5c00249
BibTeX
@article{BedregalPortugal2025,
author = {Bedregal-Portugal, Kristel and Mercier, Alexis and Stelse-Masson, Sarah and Aubrun, Clémentine and Elleaume, Hélène and Verry, Camille and Bulin, Anne-Laure},
title = {Nanoscintillators as Next-Generation Radiotherapeutics: Bridging Physics, Chemistry, and Oncology},
journal = {Bioconjugate Chemistry},
year = {2025},
doi = {10.1021/acs.bioconjchem.5c00249}
}
EUVIMED